Montreux, Switzerland | March 1st, 2021 – MedXCell SA, a Swiss biotech portfolio company dedicated to transforming healthcare through the development and production of innovative, and affordable off-the-shelf cellular therapies, announced the arrival of Prof. Guillaume Cartron as Scientific and Clinical Advisor.
Prof. Guillaume Cartron received his MD and Ph.D. from the University François Rabelais of Tours, France and qualified as a specialist in Hematology. He is the head of the department of clinical hematology at the university hospital of Montpellier, where he has developed state of the art clinical expertise in the diagnosis and treatment of lymphoproliferative disorders as well as the development of new immunotherapy materials and protocols.
Prof. Guillaume Cartron got involved very early in the field of immunotherapy and particularly in understanding the mechanisms of action of monoclonal antibodies. He was the first to demonstrate the role of ADCC and particularly of NK-cells in the therapeutic activity of anti-CD20 monoclonal antibodies via its interaction with CD16. The impact of Prof. Cartron’s work has largely contributed to the development of new generation of anti-CD20 antibodies and in particular, forms modified for their affinity with CD16 express by NK-cells. He is a consultant for many manufacturers developing monoclonal antibodies and participates in the SAB of several companies involved in the development of new cell and gene therapies. He is the author of numerous articles in the fields of immunotherapy and the treatment of lymphoma.
Prof. Cartron is a founding member of LYSA, and member of its scientific council, as well as head of the scientific committee for indolent lymphomas. Moreover, he is the president of the Carnot Lymphoma Institute (CALYM) which brings together all the French research teams involved in research on lymphomas and their treatment. Last but not least, he’s the director of the EVOCAN University Hospital Federation which brings together 300 researchers from the University of Montpellier involved in cancer research.
Prof. Guillaume Cartron will bring significant value to the MedXCell Group. His long expertise as a clinician will help MedXCell build a coherent product portfolio responding to concrete patient’s needs. As a CAR-T and immunotherapy expert, Prof. Guillaume Cartron will unquestionably help MedXCell NKar enter clinical trials more rapidly and effectively.
Alan Cookson, CTO of the group said “It is a privilege to be able to work with Prof. Cartron. With his expertise, MedXCell will be able to accelerate its development of innovative cell therapy products in the oncology field. In addition, his experience – close to the patient – will keep the company focused on delivering new innovations and products that have the potential to treatment options and change lives for the better”. Prof. Guillaume Cartron added “At the University of Montpellier we were able to create a scientific story, but now with MedXCell SA, we will create a medical story”.
For business inquiries or questions, please contact: